Authors: Martha Powell, Future Science Group
A team at Université catholique de Louvain (UCLouvin; Belgium) have reported that intestinal bacteria, Akkermansia muciniphila, could limit the increase of cardiovascular risk factors in a first in-human study.
In 2007 Akkermansia muciniphila was reported by UCLouvin to moderate obesity and type 2 diabetes in mice. Following this, the team discovered that use of a pasteurized form of Akkermansia led to greater protection compared with the living bacterium regarding cardiovascular risk factors such as insulin resistance, storage of fat or hypercholesterolemia.
Following these findings, the team from UCLouvin, in collaboration with the Cliniques Universitaires Saint-Luc (Belgium), developed a clinical study that would administer and assess these bacteria in humans.